Exosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Exosome Type (Natural v/s Hybrid), By Source (Mesenchymal Stem Cells, Blood, Body Fluids, Others), By Therapy (Immunotherapy, Chemotherapy, Gene Therapy), By Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Others), By End User (Hospitals & Clinics, Academics & Research Institutions, Others), By Region

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Global exosome therapeutics market is anticipated to advance at a steady CAGR in the forecast period, 2024-2028. This can be ascribed due to the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, autoimmune diseases across the globe. Exosomes are designed to deliver a variety of therapeutic payloads, including chemotherapeutic drugs, immunological modulators, antisense oligonucleotides, short interfering RNAs (RNAs), and antisense oligonucleotides. Also, the global exosome therapeutics market is expanding due to the rise in the usage of exosome therapy's multifunctional properties for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and chronic heart failure. Besides, growing research & development activities initiated by various biotechnology & pharmaceutical companies and academic & research institutions worldwide are expected to create lucrative opportunities for the growth of the global exosome therapeutics market in the coming years. According to clinicaltrials.gov, currently, there are 25 clinical trials related to exosome therapeutics going on worldwide that are in different phases of development. Exosomes can be isolated from a variety of cell types, including stem cells, immune cells, and cancer cells. Once isolated, exosomes can be engineered to target specific cells or tissues, making them a promising therapeutic tool for a range of diseases, including cancer, neurological disorders, and cardiovascular diseases. One of the key advantages of exosome therapeutics is their ability to target specific cells or tissues. This targeted delivery reduces the potential for off-target effects and can improve the efficacy of the therapy. Additionally, exosomes are non-immunogenic, meaning that they can be used in allogeneic therapies without the risk of rejection.Despite the growing interest in exosomes, there is still a limited understanding of their biology and mechanisms of action. This has hindered the development of effective therapies and diagnostic tools. There is currently a lack of standardized protocols for the isolation and characterization of exosomes, which can lead to inconsistencies in product quality and hinder regulatory approval. The production of exosome therapeutics can be costly due to the need for specialized equipment and expertise, which can limit their accessibility and affordability. Although preclinical studies have shown promising results for exosome therapeutics, there is still a limited amount of clinical data available. This can make it difficult to demonstrate their safety and efficacy in human patients. Despite the supportive regulatory environment, there are still regulatory challenges that need to be addressed, including the need for standardized protocols and the demonstration of safety and efficacy in clinical trials. The exosome therapeutics market faces competition from other emerging therapies, such as gene therapies and cell-based therapies, which can limit their market potential.

Increasing Prevalence of Chronic Diseases

The growth in the prevalence of chronic diseases, infectious diseases, autoimmune diseases, and cancer, as well as the increase in the demand for molecular diagnosis, are the main factors driving the exosome diagnostic and therapeutic market share. Additionally, ongoing developments in drug development and discovery in exosome innovation provide valuable insights into biological heterogeneity and function and improve the capacity to utilize the therapeutic and diagnostic potential for infectious disease and cancer. Therefore, the development of the exosome diagnostic and therapeutic markets is driven by technological improvement in the healthcare industry. Unhealthy eating habits, tobacco consumption, and lack of physical activity are only a few of the key causes of cardiovascular disease, which increase blood pressure and blood glucose levels, resulting in overweight and obesity which will further increase the rate of chronic diseases and demanding for exosome therapeutics in the forecast period. The growing prevalence of cardiovascular illnesses has led to an increase in the need for exosome diagnostic and therapeutic products (CVDs). This is a result of the development of more durable technologically advanced devices. According to Globocan, From the total number of 2,281,658 effected skin cancer diseases across the globe 4.2% are effected in melanoma skin cancer, 6.8% are effected in colorectum cancer, 9.2% are effected in prostate cancer, 10% are effected in lung cancer, 11.1% are effected in breast cancer and 58.7% are effected in other cancer. The global prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular diseases is increasing, leading to a rising demand for effective and targeted therapies. Exosome therapeutics offer a promising solution for these diseases, as they can be used for targeted drug delivery and regenerative medicine. The exosome therapeutics market has witnessed significant investments in research and development activities by major pharmaceutical and biotech companies. This has led to the development of new therapies and diagnostic tools, driving the growth of the market. The trend towards personalized medicine is driving the demand for targeted therapies that can be tailored to individual patients. Exosome therapeutics offer a promising solution for personalized medicine, as they can be engineered to target specific cells or tissues. The global geriatric population is increasing, leading to a rising incidence of age-related diseases such as Alzheimer's and Parkinson's disease. Exosome therapeutics offer a potential solution for these diseases, as they can be used to deliver therapeutic agents to the brain.

Growing research and development

Several initiatives such as setting up policies for the development of new therapies along with the rise in funds, are taken by governments across the world to support the healthcare industry. The government is launching different programs to provide better technology, improve treatment techniques, and improve product development and processing technologies. In addition, the rapid technological advancements in exosome therapeutics and the growth of the target patient population are also contributing to the growth in the global market over the forecast period of 2024 to 2028. According to American Cancer Society, , in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. In January 2020, Kimera Labs received the FDA approval for the purest mesenchymal stem cell (MSC) exosomes in existence. The approval received would ensure strict compliance with good laboratory practices (GLPs) and current good manufacturing practice (CGMP) standards to enable the production of pharmaceutical-grade exosomes for investigational trials and the development of future clinical applications. There have been significant advancements in the isolation and characterization of exosomes, including the development of new techniques and tools for their analysis. This has led to improved product quality and consistency, and has facilitated regulatory approval. There has been an expansion of clinical trials for exosome therapeutics in a variety of indications, including cancer, neurological disorders, and cardiovascular diseases. These trials have shown promising results, and have helped to demonstrate the safety and efficacy of exosome therapeutics in human patients. There has been a significant increase in investment and partnerships in the exosome therapeutics market, including collaborations between academic institutions and pharmaceutical companies. This has led to increased research and development, and has helped to accelerate the commercialization of exosome therapeutics. There has been an emergence of exosome-based diagnostic tools, including liquid biopsy tests, which can detect cancer and other diseases by analyzing exosomes in bodily fluids. These tests offer a non-invasive alternative to traditional diagnostic methods, and have the potential to improve patient outcomes. Several exosome therapeutics have received regulatory approval in recent years, including the first-ever exosome-based therapy for a rare pediatric disease. These approvals have helped to establish the safety and efficacy of exosome therapeutics, and have paved the way for further commercialization.

Recent Development

  • In 2021, Evox Therapeutics launched the EVOGENE® Exosome RNA Delivery System, a platform that utilizes exosomes for the targeted delivery of RNA therapeutics. The system is designed to improve the efficacy and safety of RNA therapeutics by delivering them directly to specific cells or tissues.
  • In 2019, Exosome Diagnostics launched the ExoDx Prostate IntelliScore (EPI) test, a liquid biopsy test that analyzes exosomes in urine samples to determine the likelihood of high-grade prostate cancer. The test offers a non-invasive alternative to traditional diagnostic methods, and has the potential to improve patient outcomes by identifying cancer earlier.
  • In 2018, Exopharm launched the Plexaris™ exosome isolation and purification system, a tool for the rapid and efficient isolation of exosomes from biological samples. The system utilizes a proprietary technology to isolate and purify exosomes without the need for ultracentrifugation or other complex methods, and is designed to facilitate research and development in the field of exosome therapeutics.


Download Free Sample Report

Market Segmentation

Global exosome therapeutics market is segmented into exosome type, source, therapy, application, end user, regional distribution and competitive landscape. Based on exosome type, the market is divided into Natural exosome therapy and Hybrid exosome therapy. Based on source, the market is divided into Mesenchymal stem cells, Blood, Body fluids, and others. Based on therapy, the market is divided into Immunotherapy, Chemotherapy, Gene Therapy. Based on application, the market is divided into Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, and Others. Based on end user, the market is divided into hospitals & clinics, academic & research institutions, others. In terms of country, the United States is expected to be a lucrative market in the forecast period as the government is investing in new exosome therapeutics for the easy detection of chronic disease unaffected people.

Market Players

Aethlon Medical, Inc.-Exosome Sciences, Aegle Therapeutics, Anjarium Biosciences AG, Exogenus Therapeutics SA, Lonza Group, Capricor Therapeutics, Inc., Avalon Globocare Corp, Stem Cell Medicine Ltd., Evox Therapeutics Limited, EV Therapeutics are some of the leading players operating in the global exosome therapeutics market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         By Exosome Type

·         By Source

·         By Therapy

·         By Application

·         By End User

Regional scope

North America; Asia Pacific; Europe; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Italy; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia;

Key companies profiled

Aethlon Medical, Inc.-Exosome Sciences, Aegle Therapeutics, Anjarium Biosciences AG, Exogenus Therapeutics SA, Lonza Group, Capricor Therapeutics, Inc., Avalon Globocare Corp, Stem Cell Medicine Ltd., Evox Therapeutics Limited, EV Therapeutics

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, global exosome therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Exosome Therapeutics Market, By Type:

o   Natural

o   Hybrid

  • Exosome Therapeutics Market, By Source:

o    Mesenchymal Stem Cells

o    Blood,

o    Body Fluids,

o    Others

  • Exosome Therapeutics Market, By Therapy :

o    Immunotherapy

o    Chemotherapy

o    Gene Therapy

  • Exosome Therapeutics Market, By Application:

o    Metabolic Disorders

o    Oncology

o    Cardiac Disorders

o    Neurology

o    Others

  • Exosome Therapeutics Market, By End User:

o    Hospitals & Clinics

o    Academic & Research Institutions

o    Others

  • Exosome Therapeutics Market, By Region:

o    North America

    • United States
    • Canada
    • Mexico

o    Asia-Pacific

    • China
    • India
    • Japan
    • South Korea
    • Australia

o    Europe

    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy

o    South America

    • Brazil
    • Argentina
    • Colombia

o    Middle East & Africa

    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global exosome therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global electric train market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected].


Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Clinical Trial Analysis

5.1.  Ongoing Clinical Trials

5.2.  Completed Clinical Trials

5.3.  Terminated Clinical Trials

5.4.  Breakdown of Pipeline, By Development Phase

5.5.  Breakdown of Pipeline, By Status

5.6.  Breakdown of Pipeline, By Study Application

5.7.  Breakdown of Pipeline, By Region

5.8.  Clinical Trials Heat Map

6.    Global Exosome Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Exosome Type (Natural v/s Hybrid)

6.2.2.     By Source (Mesenchymal Stem Cells, Blood, Body Fluids, Others)

6.2.3.     By Therapy (Immunotherapy, Chemotherapy, Gene Therapy)

6.2.4.     By Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Others)

6.2.5.     By End User (Hospitals & Clinics, Academic & Research Institutions, Others)

6.2.6.     By Company (2021)

6.2.7.     By Region

6.3.  Market Map

7.    North America Exosome Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Exosome Type

7.2.2.     By Source

7.2.3.     By Therapy

7.2.4.     By Application

7.2.5.     By End User

7.2.6.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Exosome Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Exosome Type

7.3.1.2.2.             By Source

7.3.1.2.3.             By Therapy

7.3.1.2.4.             By Application

7.3.1.2.5.             By End User

7.3.2.     Mexico Exosome Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Exosome Type

7.3.2.2.2.             By Source

7.3.2.2.3.             By Therapy

7.3.2.2.4.             By Application

7.3.2.2.5.             By End User

7.3.3.     Canada Exosome Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Exosome Type

7.3.3.2.2.             By Source

7.3.3.2.3.             By Therapy

7.3.3.2.4.             By Application

7.3.3.2.5.             By End User

8.    Europe Exosome Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Exosome Type

8.2.2.     By Source

8.2.3.     By Therapy

8.2.4.     By Application

8.2.5.     By End User

8.2.6.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Exosome Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Exosome Type

8.3.1.2.2.             By Source

8.3.1.2.3.             By Therapy

8.3.1.2.4.             By Application

8.3.1.2.5.             By End User

8.3.2.     Germany Exosome Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Exosome Type

8.3.2.2.2.             By Source

8.3.2.2.3.             By Therapy

8.3.2.2.4.             By Application

8.3.2.2.5.             By End User

8.3.3.     United Kingdom Exosome Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Exosome Type

8.3.3.2.2.             By Source

8.3.3.2.3.             By Therapy

8.3.3.2.4.             By Application

8.3.3.2.5.             By End User

8.3.4.     Italy Exosome Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Exosome Type

8.3.4.2.2.             By Source

8.3.4.2.3.             By Therapy

8.3.4.2.4.             By Application

8.3.4.2.5.             By End User

8.3.5.     Spain Exosome Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Exosome Type

8.3.5.2.2.             By Source

8.3.5.2.3.             By Therapy

8.3.5.2.4.             By Application

8.3.5.2.5.             By End User

9.    Asia-Pacific Exosome Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Exosome Type

9.2.2.     By Source

9.2.3.     By Therapy

9.2.4.     By Application

9.2.5.     By End User

9.2.6.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Exosome Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Exosome Type

9.3.1.2.2.             By Source

9.3.1.2.3.             By Therapy

9.3.1.2.4.             By Application

9.3.1.2.5.             By End User

9.3.2.     India Exosome Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Exosome Type

9.3.2.2.2.             By Source

9.3.2.2.3.             By Therapy

9.3.2.2.4.             By Application

9.3.2.2.5.             By End User

9.3.3.     Japan Exosome Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Exosome Type

9.3.3.2.2.             By Source

9.3.3.2.3.             By Therapy

9.3.3.2.4.             By Application

9.3.3.2.5.             By End User

9.3.4.     South Korea Exosome Therapeutics Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Exosome Type

9.3.4.2.2.             By Source

9.3.4.2.3.             By Therapy

9.3.4.2.4.             By Application

9.3.4.2.5.             By End User

9.3.5.     Australia Exosome Therapeutics Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Exosome Type

9.3.5.2.2.             By Source

9.3.5.2.3.             By Therapy

9.3.5.2.4.             By Application

9.3.5.2.5.             By End User

10.  South America Exosome Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Exosome Type

10.2.2.  By Source

10.2.3.  By Therapy

10.2.4.  By Application

10.2.5.  By End User

10.2.6.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Exosome Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Exosome Type

10.3.1.2.2.           By Source

10.3.1.2.3.           By Therapy

10.3.1.2.4.           By Application

10.3.1.2.5.           By End User

10.3.2.  Argentina Exosome Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Exosome Type

10.3.2.2.2.           By Source

10.3.2.2.3.           By Therapy

10.3.2.2.4.           By Application

10.3.2.2.5.           By End User

10.3.3.  Colombia Exosome Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Exosome Type

10.3.3.2.2.           By Source

10.3.3.2.3.           By Therapy

10.3.3.2.4.           By Application

10.3.3.2.5.           By End User

11.  Middle East and Africa Exosome Therapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Exosome Type

11.2.2.  By Source

11.2.3.  By Therapy

11.2.4.  By Application

11.2.5.  By End User

11.2.6.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Exosome Therapeutics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Exosome Type

11.3.1.2.2.           By Source

11.3.1.2.3.           By Therapy

11.3.1.2.4.           By Application

11.3.1.2.5.           By End User

11.3.2.  Saudi Arabia Exosome Therapeutics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Exosome Type

11.3.2.2.2.           By Source

11.3.2.2.3.           By Therapy

11.3.2.2.4.           By Application

11.3.2.2.5.           By End User

11.3.3.  UAE Exosome Therapeutics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Exosome Type

11.3.3.2.2.           By Source

11.3.3.2.3.           By Therapy

11.3.3.2.4.           By Application

11.3.3.2.5.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

13.1.              Recent Developments

13.2.              Mergers & Acquisitions

13.3.              Product Launches

14.  Competitive Landscape

14.1.              Business Overview

14.2.              Company Snapshot

14.3.              Products & Services

14.4.              Financials (As reported)

14.5.              Recent Developments

14.6.              SWOT Analysis

14.6.1.  Aethlon Medical, Inc.-Exosome Sciences

14.6.2.  Aegle Therapeutics

14.6.3.  Anjarium Biosciences AG

14.6.4.  Exogenus Therapeutics SA

14.6.5.  Lonza Group

14.6.6.  Capricor Therapeutics, Inc.

14.6.7.  Avalon Globocare Corp

14.6.8.  Stem Cell Medicine Ltd.

14.6.9.  Evox Therapeutics Limited

14.6.10.   EV Therapeutics

Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

An increasing number of autoimmune disease and excessive use of molecular diagnosis and different technology development in research and development sectors are driving the demand for the global exosome therapeutics market.

down-arrow

Aethlon Medical, Inc.-Exosome Sciences, Aegle Therapeutics, Anjarium Biosciences AG, Exogenus Therapeutics SA, Lonza Group, Capricor Therapeutics, Inc., Avalon Globocare Corp, Stem Cell Medicine Ltd., Evox Therapeutics Limited, EV Therapeutics are the leading players operating in the global exosome therapeutics market.

down-arrow

Hybrid Exosome Type is expected to dominate the growth of the market during the forecasted period.

down-arrow

The North American region is dominating the market and is expected to maintain its dominance over the next five years.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Exosome Therapeutics Market to be Dominated By Hybrid Exosome Therapy through 2028

Dec, 2022

Increasing molecular diagnosis and the emerging role of exosomes in the treatment of chronic diseases to drive the global exosome therapeutics market in the forecast period 2024-2028.

Why Choose Us